Follow the people · Insider
Timothy P. Lynch
Timothy P. Lynch files insider transactions with the SEC as a 10% owner of AEON Biopharma (AEON). We hold 1 disclosed purchase or sale filed since 12 May 2006, 1 of them in the last 90 days.
- Files forAEON
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure21 August 2026
Positions held
7 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 19 August 2026 — 19 August 202610% owner · AEON Biopharma (AEON)1 Form 4 line · source: SEC Form 4
- Filed 10 May 2006 — 21 June 2011Director · Allos Therapeutics (ALTH)6 Form 4 lines · source: SEC Form 4
- Filed 10 November 2006 — 25 May 2011Director · Nabi Biopharmaceuticals (NABI)8 Form 4 lines · source: SEC Form 4
- Filed 16 December 2009 — 20 December 2010Director · Insite Vision (INSV)2 Form 4 lines · source: SEC Form 4
- Filed 9 November 2007 — 16 February 2010Director · Bioform Medical (BFRM)12 Form 4 lines · source: SEC Form 4
- Filed 23 September 2008 — 23 September 2008Director · Insite Vision (ISV)1 Form 4 line · source: SEC Form 4
- Filed 2 January 2008 — 1 July 2008Director · Aradigm (ARDM)3 Form 4 lines · source: SEC Form 4
Everything they disclosed
33 entries, newest first — one per disclosure report, one per Form 4 line- ▲ bought on the open market 1,150,000 shares of AEON BiopharmaSEC Form 421 August 2026Class A Common Stock · traded 19 August 2026 · filed 21 August 2026
- was granted 20,000 shares of Allos Therapeutics (a derivative holding)SEC Form 423 June 2011Stock Options (Right to Buy) · traded 21 June 2011 · filed 23 June 2011
- was granted 20,000 shares of Nabi Biopharmaceuticals (a derivative holding)SEC Form 427 May 2011Stock Option (right to buy) · traded 25 May 2011 · filed 27 May 2011
- was granted 150,000 shares of Insite Vision (a derivative holding)SEC Form 422 December 2010Stock Option (right to buy) · traded 20 December 2010 · filed 22 December 2010
- was granted 20,000 shares of Allos Therapeutics (a derivative holding)SEC Form 424 June 2010Stock Options (Right to Buy) · traded 22 June 2010 · filed 24 June 2010
- was granted 20,000 shares of Nabi Biopharmaceuticals (a derivative holding)SEC Form 424 May 2010Stock Option (right to buy) · traded 20 May 2010 · filed 24 May 2010
- returned to the issuer 10,000 shares of Bioform Medical (a derivative holding)SEC Form 419 February 2010Director Stock Option (Right to Buy) · traded 16 February 2010 · filed 19 February 2010
- returned to the issuer 10,000 shares of Bioform Medical (a derivative holding)SEC Form 419 February 2010Director Stock Option (Right to Buy) · traded 16 February 2010 · filed 19 February 2010
- returned to the issuer 35,000 shares of Bioform Medical (a derivative holding)SEC Form 419 February 2010Director Stock Option (Right to Buy) · traded 16 February 2010 · filed 19 February 2010
- returned to the issuer 6,500 shares of Bioform Medical (a derivative holding)SEC Form 419 February 2010Director Stock Option (Right to Buy) · traded 16 February 2010 · filed 19 February 2010
- disposed of in a tender offer 45,454 shares of Bioform MedicalSEC Form 419 February 2010Common Stock · traded 16 February 2010 · filed 19 February 2010
- was granted 10,000 shares of Bioform Medical (a derivative holding)SEC Form 429 December 2009Director Stock Option (Right to Buy) · traded 10 December 2009 · filed 29 December 2009
- converted 45,454 shares of Bioform MedicalSEC Form 429 December 2009Common Stock · traded 9 November 2007 · filed 29 December 2009
- was granted 150,000 shares of Insite Vision (a derivative holding)SEC Form 418 December 2009Stock Option (right to buy) · traded 16 December 2009 · filed 18 December 2009
- ▼ sold on the open market 3,846 shares of Nabi BiopharmaceuticalsSEC Form 418 November 2009Common Stock · traded 17 November 2009 · filed 18 November 2009
- was granted 20,000 shares of Allos Therapeutics (a derivative holding)SEC Form 423 June 2009Stock Options (Right to Buy) · traded 23 June 2009 · filed 23 June 2009
- was granted 20,000 shares of Nabi Biopharmaceuticals (a derivative holding)SEC Form 427 May 2009Stock Option (right to buy) · traded 22 May 2009 · filed 27 May 2009
- converted 45,454 shares of Bioform Medical (a derivative holding)SEC Form 416 December 2008Series E Convertible Preferred Stock · traded 9 November 2007 · filed 16 December 2008
- was granted 10,000 shares of Bioform Medical (a derivative holding)SEC Form 416 December 2008Director Stock Option (Right to Buy) · traded 12 December 2008 · filed 16 December 2008
- converted 45,454 shares of Bioform MedicalSEC Form 416 December 2008Common Stock · traded 9 November 2007 · filed 16 December 2008
- was granted 30,000 shares of Insite Vision (a derivative holding)SEC Form 425 September 2008Stock Option (right to buy) · traded 23 September 2008 · filed 25 September 2008
- acquired or disposed of, other 240,000 shares of AradigmSEC Form 49 July 2008Common Stock · traded 1 July 2008 · filed 9 July 2008
- was granted 20,000 shares of Aradigm (a derivative holding)SEC Form 427 June 2008Option (Right to Buy) · traded 15 May 2008 · filed 27 June 2008
- was granted 20,000 shares of Allos Therapeutics (a derivative holding)SEC Form 426 June 2008Stock Options (Right to buy) · traded 24 June 2008 · filed 26 June 2008
- was granted 20,000 shares of Nabi Biopharmaceuticals (a derivative holding)SEC Form 49 June 2008Stock Option (right to buy) · traded 7 May 2008 · filed 9 June 2008
- was granted 30,000 shares of Aradigm (a derivative holding)SEC Form 43 January 2008Option (Right to Buy) · traded 2 January 2008 · filed 3 January 2008
- converted 45,454 shares of Bioform Medical (a derivative holding)SEC Form 414 November 2007Series E Convertible Preferred Stock · traded 9 November 2007 · filed 14 November 2007
- converted 45,454 shares of Bioform MedicalSEC Form 414 November 2007Common Stock · traded 9 November 2007 · filed 14 November 2007
- was granted 20,000 shares of Allos Therapeutics (a derivative holding)SEC Form 421 June 2007Stock Options (Right to buy) · traded 19 June 2007 · filed 21 June 2007
- was granted 20,000 shares of Nabi Biopharmaceuticals (a derivative holding)SEC Form 422 May 2007Stock Option (right to buy) · traded 18 May 2007 · filed 22 May 2007
- was granted 3,846 shares of Nabi BiopharmaceuticalsSEC Form 422 May 2007Common Stock · traded 18 May 2007 · filed 22 May 2007
- was granted 18,000 shares of Nabi Biopharmaceuticals (a derivative holding)SEC Form 414 November 2006Stock Option (right to buy) · traded 10 November 2006 · filed 14 November 2006
- was granted 20,000 shares of Allos Therapeutics (a derivative holding)SEC Form 412 May 2006Stock Options (Right to buy) · traded 10 May 2006 · filed 12 May 2006
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.